Insulin resistance, non-alcoholic fatty liver disease and hepatitis c virus infection

Reviews on Recent Clinical Trials

Volumn 9, Issue 3, 2014, Pages 204-209

  Goossens, Nicolas ^a   Negro, Francesco ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Fibrosis; Hepatitis C virus; Non alcoholic fatty liver disease; Steatosis

Indexed keywords

ARTICLE; DISEASE ASSOCIATION; DISEASE CONTROL; GLUCOSE METABOLISM; HEPATITIS C; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER FIBROSIS; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); VIRUS INFECTION; CHRONIC HEPATITIS C; METABOLISM;

HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84922322677     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887109666141216101939     Document Type: Article

References (64)

1. [1] Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence. Hepatology 2013; 57(4): 1333-42.
2. [2] Lee M-H, Yang H-I, Lu S-N, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-77.
3. [3] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
4. [4] Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services 2014.
5. [5] Leandro G, Mangia A, Hui J, Fabris P, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data. Gastroenterology 2006; 130(6): 1636-42.
6. [6] Bochud P-Y, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51(4): 655-66.
7. [7] Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology 2006; 44(17133473): 1648-55.
8. [8] White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49(5): 831-44.
9. [9] Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008; 31(1): 165-9.
10. [10] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10(6): 330-44.
11. [11] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55(6): 2005-23.
12. [12] Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36(5): 1266-72.
13. [13] Poynard T, Ratziu V, McHutchison J, Manns M, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38(1): 75-85.
14. [14] Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33(6): 1358-64.
15. [15] Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54(7): 1003-8.
16. [16] Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study. Hepatology 2007; 46(2): 380-7.
17. [17] Dienes HP, Popper H, Arnold W, Lobeck H. Histologic observations in human hepatitis non-A, non-B. Hepatology 1982; 2(6811393): 562-71.
18. [18] Wiese M, Haupt R. [Histomorphologic picture of chronic non-A, non-B hepatitis]. Dtsch Z Verdau Stoffwechselkr 1985; 45(3930205): 101-10.
19. [19] Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Hostand diseasespecific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29(2): 198-206.
20. [20] Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008; 23(18707599): 1082-8.
21. [21] Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33(1): 106-15.
22. [22] Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014; 59(6): 2403-12.
23. [23] Abid K, Pazienza V, de Gottardi A, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 2005; 42(5): 744-51.
24. [24] Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16(2): 185-94.
25. [25] Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterolog 2006; 130(6): 1661-9.
26. [26] Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97(12425563): 2880-5.
27. [27] Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome?. Internal and emergency medicine 2008; (2): 9-108.
28. [28] Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114(2): 147-52.
29. [29] Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115(5): 1343-51.
30. [30] Vanni E, Abate ML, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009; 50(3): 697-706.
31. [31] Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138(3): 932-41
32. [32] Adinolfi LE, Restivo L, Zampino R, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012; 221(22385985): 496-502.
33. [33] Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010; 59(9): 1279-87.
34. [34] Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38(1): 50-6.
35. [35] Chen T, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009; 22(4): 408-15.
36. [36] Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49(3): 739-44.
37. [37] Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48(5): 721-7.
38. [38] Giordanino C, Bugianesi E, Smedile A, et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008; 103(10): 2481-7.
39. [39] Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59(4): 1293-302.
40. [40] Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Rev Gastroenterol Hepatol 2011; 5(4): 503-16.
41. [41] Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125(6): 1695-704.
42. [42] Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134(2): 416-23.
43. [43] Tanaka N, Nagaya T, Komatsu M, et al. Insulin resistance and hepatitis C virus: a case-control study of non-obese, non-alcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase. Liver Int 2008; 28(8): 1104-11.
44. [44] Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59(20660697): 1410-5.
45. [45] Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 2014; 60(3): 823-31.
46. [46] Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34(11584370): 738-44.
47. [47] Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: Does it matter? J hepatol 2012; 56: S56-65.
48. [48] Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55(6): 1554-61.
49. [49] El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4(3): 369-80.
50. [50] Chen C-L, Yang H-I, Yang W-S, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135(18505690): 111-21.
51. [51] Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57(3): 964-73.
52. [52] Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105(9): 1970-7.
53. [53] Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34(3): 297-305.
54. [54] Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012; 56(2): 464-73.
55. [55] Romero-Gomez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50(6): 1702-8.
56. [56] Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatmentnaive patients infected with HCV genotype 1. Gut 2012; 61(10): 1473-80.
57. [57] Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010; 59(12): 1694-8.
58. [58] Younossi Z, Negro F, Serfaty L, et al. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology 2013; 58(6): 1897-906.
59. [59] Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46(17335930): 1126-32.
60. [60] Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010; 59(20584782): 1135-40.
61. [61] Lee MH, Yang HI, Wang CH, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41(12): 2894-900.
62. [62] Alyan O, Kacmaz F, Ozdemir O, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008; 72(12): 1960-5.
63. [63] Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167(6): 743-50.
64. [64] Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61(1): 69-78.